VT-1021 is under clinical development by Vigeo Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 10% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VT-1021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VT-1021 is under development for the treatment of solid tumors including epithelial ovarian, fallopian tube, or primary peritoneal cancer, pancreatic ductal adenocarcinoma, triple-negative breast cancer and glioblastoma. The drug candidate comprises of D-psaptide and cyclopsaptide, derived from naturally-occurring human protein, prosaposin. It acts by targeting CD36 receptor and Leukocyte Surface Antigen CD47. It is administered through intravenous route.
Vigeo Therapeutics overview
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors. The company is headquartered in Boston, Massachusetts, the US
For a complete picture of VT-1021’s drug-specific PTSR and LoA scores, buy the report here.